Study of CLN-978 for people with systemic lupus erythematosus
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This trial tests an experimental drug called CLN-978, given as a shot under the skin, that targets a protein on certain immune cells (B cells) to try to calm overactive immune activity in lupus. The goal is to see if it can reduce lupus symptoms for people whose disease has not been controlled by other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with lupus (SLE) for at least 6 months
- Your lupus must be active, with a score of 6 or more on a lupus activity scale (SLEDAI)
- You must have tried at least two different lupus treatments (like steroids, hydroxychloroquine, immunosuppressants, or biologics) and they did not work well enough
- You must have certain lupus-related antibodies in your blood (like ANA, anti-dsDNA, or anti-Sm)
- You must have enough immune cells in your blood, including B cells (at least 25 per microliter) and lymphocytes (at least 500 per microliter)
- Your kidney, liver, and blood cell counts must be within safe ranges
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called CRC01, made from your own cells, for people with severe lupus that hasn't improved with standard medications. The goal is to see if it can safely control the disease and reduce symptoms.
This trial tests a new treatment for people with active lupus who haven't responded well to steroids and at least two other immune-suppressing drugs, including a biologic. It aims to find a better option for controlling lupus symptoms.
This trial tests an experimental drug called CLN-978, given as a shot under the skin, that helps your immune system target and destroy disease-causing B cells. It's for people with moderate to severe Sjögren's disease who haven't had success with other treatments.
This trial tests a new medicine called CLN-978, given as an injection under the skin, to see if it can help people with active rheumatoid arthritis who haven't improved enough with other treatments. CLN-978 works by targeting a specific immune cell to reduce inflammation.
This trial tests an investigational drug called QLS4131 in people with active systemic lupus erythematosus (SLE) who are already on standard treatments. The goal is to see if adding QLS4131 can help control lupus activity better.
This study tests a new injectable medicine (SG301) for people with lupus (SLE) whose current treatments are not working well enough or cause side effects. It aims to see if this targeted therapy can better control lupus symptoms.
Hear when a new SLE (Systemic Lupus) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.